Development of fluorizoline analogues as prohibitin ligands that modulate C-RAF signaling, p21 expression and melanogenesis.

Fiche publication

Date publication

août 2022

Journal

European journal of medicinal chemistry

Auteurs

Membres identifiés du Cancéropôle Est :
Dr DESAUBRY Laurent , Dr NEBIGIL-DESAUBRY Canan

Tous les auteurs :
Chouha N, Abou-Hamdan H, Yurugi H, Yoshii R, Ii H, Najem A, Ghanem GE, Nakata S, Rajalingam K, Peng Y, Wang D, Nebigil CG, Désaubry L

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/35988448

Résumé

Fluorizoline is a cytotoxic trifluorothiazoline that targets the scaffold proteins prohibitins-1 and -2 (PHB1/2) to inhibit the kinase C-RAF and promote the expression of the cyclin-dependent kinase inhibitor p21 to induce cancer cell death. In melanocytes, fluorizoline also induces the synthesis of melanin. Herein we report the first structural requirement of fluorizoline analogues for these activities. We identified in particular some compounds that display enhanced anti-C-RAF and anti-MEK activities, and a higher cytotoxicity in HeLa cells compared to fluorizoline. These results provide a foundation for further optimization of PHB ligands for the treatment of cancers. We also discovered an analogue of fluorizoline that displays pharmacological effects opposed to those of fluorizoline and that can be used as a chemical tool to explore PHB signaling in cancers and other diseases.